Human pharmacogenomic variations and their implications for antifungal efficacy

Clinical Microbiology Reviews

Volumn 19, Issue 4, 2006, Pages 763-787

  Meletiadis, Joseph ^a   Chanock, Stephen ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CIMETIDINE; CYCLOSPORIN; DIDANOSINE; DOMPERIDONE; ECHINOCANDIN; ETOPOSIDE; FAMOTIDINE; FLUCONAZOLE; FLUCYTOSINE; HISTAMINE H2 RECEPTOR ANTAGONIST; ITRACONAZOLE; LIPOPROTEIN; LOPERAMIDE; MICAFUNGIN; OROSOMUCOID; PACLITAXEL; POSACONAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RAVUCONAZOLE; SUCRALFATE; TERBINAFINE; UNINDEXED DRUG; VINBLASTINE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; BILIARY EXCRETION; DRUG ABSORPTION; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; ENVIRONMENTAL FACTOR; GENDER; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; PHARMACOGENOMICS; REVIEW; STEREOCHEMISTRY; STOMACH PH; URINARY EXCRETION;

ANTIFUNGAL AGENTS; DRUG THERAPY; GENETIC VARIATION; GENOME, HUMAN; HUMANS; INTESTINAL ABSORPTION; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 33750059472     PISSN: 08938512     EISSN: None     Source Type: Journal    
DOI: 10.1128/CMR.00059-05     Document Type: Review

References (289)

1. Ahonen, J., K. T. Olkkola, and P. J. Neuvonen. 1996. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundam. Clin. Pharmacol. 10:314-318.
2. Albengres, E., H. Le Louet, and J. P. Tillement. 1998. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 18:83-97.
3. Amhudkar, S. V., C. Kimchi-Sarfaty, Z. E. Sauna, and M. M. Gottesman. 2003. Pglycoprotein: from genomics to mechanism. Oncogene 22:7468-7485.
4. Angirasa, A. K., and A. Z. Koch. 2002. P-glycoprotein as the mediator of itraconazoledigoxin interaction. J. Am. Podiatr. Med. Assoc. 92:471-472.
5. Anonymous. 2003. Posaconazole: SCH 56592. Drugs R D 4:258-263.
6. Aoyama, N., Y. Tanigawara, T. Kita, T. Sakai, K. Shirakawa, D. Shirasaka, F. Kodama, K. Okumura, and M. Kasuga. 1999. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J. Gastroenterol. 34(Suppl. 11):80-83.
7. Arndt, C. A., T. J. Walsh, C. L. McCully, F. M. Balis, P. A. Pizzo, and D. G. Poplack. 1988. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J. Infect. Dis. 157:178-180.
8. Arredondo, G., R. Calvo, F. Marcos, R. Martinez-Jorda, and E. Suarez. 1995. Protein binding of itraconazole and fluconazole in patients with cancer. Int. J. Clin. Pharmacol. Ther. 33:449-452.
9. Arredondo, G., R. Martinez-Jorda, R. Calvo, C. Aguirre, and E. Suarez. 1994. Protein binding of itraconazole and fluconazole in patients with chronic renal failure. Int. J. Clin. Pharmacol. Ther. 32:361-364.
10. Arredondo, G., E. Suarez, R. Calvo, J. A. Vazquez, J. Garcia-Sanchez, and R. Martinez-Jorda. 1999. Serum protein binding of itraconazole and fluconazole in patients with diabetes mellitus. J. Antimicrob. Chemother. 43:305-307.
11. Ayrton, A., and P. Morgan. 2001. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31:469-497.
12. Bacanu, S. A., B. Devlin, and K. Roeder. 2000. The power of genomic control. Am. J. Hum. Genet. 66:1933-1944.
13. Bader, J. S. 2001. The relative power of SNPs and haplotype as genetic markers for association tests. Pharmacogenomics 2:11-24.
14. Bahadur, N., J. B. Leathart, E. Mutch, D. Steimel-Crespi, S. A. Dunn, R. Gilissen, J. V. Houdt, J. Hendrickx, G. Mannens, H. Bohets, F. M. Williams, M. Armstrong, C. L. Crespi, and A. K. Daly. 2002. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem. Pharmacol. 64:1579-1589.
15. Baker, E. K., and A. El-Osta. 2003. The rise of DNA methylation and the importance of chromatin on multidrug resistance in cancer. Exp. Cell Res. 290:177-194.
16. Balani, S. K., X. Xu, B. H. Arison, M. V. Silva, A. Gries, F. A. DeLuna, D. Cui, P. H. Kari, T. Ly, C. E. Hop, R. Singh, M. A. Wallace, D. C. Dean, J. H. Lin, P. G. Pearson, and T. A. Baillie. 2000. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos. 28:1274-1278.
17. Baley, J. E., C. Meyers, R. M. Kliegman, M. R. Jacobs, and J. L. Blumer. 1990. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J. Pediatr. 116:791-797.
18. Beierle, I., B. Meibohm, and H. Derendorf. 1999. Gender differences in pharmacokinetics and pharmacodynamics. Int. J. Clin. Pharmacol. Ther. 37:529-547.
19. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob. Agents Chemother. 46:828-833.
20. Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh. 2002. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob. Agents Chemother. 46:834-840.
21. Benson, J. M., and M. C. Nahata. 1989. Pharmacokinetics of amphotericin B in children. Antimicrob. Agents Chemother. 33:1989-1993.
22. Bertilsson, L., T. A. Baillie, and J. Reviriego. 1990. Factors influencing the metabolism of diazepam. Pharmacol. Ther. 45:85-91.
23. Bertilsson, L., M. L. Dahl, P. Dalen, and A. Al-Shurbaji. 2002. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol. 53:111-122.
24. Blum, R. A., D. T. D'Andrea, B. M. Florentino, J. H. Wilton, D. M. Hilligoss, M. J. Gardner, E. B. Henry, H. Goldstein, and J. J. Schentag. 1991. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann. Intern. Med. 114:755-757.
25. Bohan, A., and J. L. Boyer. 2002. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Semin. Liver Dis. 22:123-136.
26. Bolard, J., M. Seigneuret, and G. Boudet. 1980. Interaction between phospholipid bilayer membranes and the polyene antibiotic amphotericin B: lipid state and cholesterol content dependence. Biochim. Biophys. Acta 599:280-293.
27. Borst, P., R. Evers, M. Kool, and J. Wijnholds. 2000. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92:1295-1302.
28. Botstein, D., and N. Risch. 2003. Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex disease. Nat. Genet. 33(Suppl):228-237.
29. Bozzette, S. A., R. L. Gordon, A. Yen, M. Rinaldi, M. K. Ito, and J. Fierer. 1992. Biliary concentrations of fluconazole in a patient with candidal cholecystitis: case report. Clin. Infect. Dis. 15:701-703.
30. Brajtburg, J., S. Elberg, J. Bolard, G. S. Kobayashi, R. A. Levy, R. E. Ostlund, Jr., D. Schlessinger, and G. Medoff. 1984. Interaction of plasma proteins and lipoproteins with amphotericin B. J. Infect. Dis. 149:986-997.
31. Brammer, K. W., and P. E. Coates. 1994. Pharmacokinetics of fluconazole in pediatric patients. Eur. J. Clin. Microbiol. Infect. Dis. 13:325-329.
32. Brammer, K. W., P. R. Farrow, and J. K. Faulkner. 1990. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 12(Suppl. 3):S318-S326.
33. Brunskill, N. 2001. Mechanisms of albumin uptake by proximal tubular cells. Am. J. Kidney Dis. 37:S17-S20.
34. Caporaso, N. E., C. Lerman, J. Audrain, N. R. Boyd, D. Main, H. J. Issaq, B. Utermahlan, R. T. Falk, and P. Shields. 2001. Nicotine metabolism and CYP2D6 phenotype in smokers. Cancer Epidemiol. Biomarkers Prev. 10:261-263.
35. Carlson, C. S., M. A. Eberle, M. J. Rieder, J. D. Smith, L. Kruglyak, and D. A. Nickerson. 2003. Additional SNPs and linkage-disequilibrium analyses are necessary for whole-genome association studies in humans. Nat. Genet. 33:518-521.
36. Cassidy, S. M., F. W. Strobel, and K. M. Wasan. 1998. Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins. Antimicrob. Agents Chemother. 42:1878-1888.
37. Cattaneo, D., N. Perico, and G. Remuzzi. 2004. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am. J. Transplant. 4:299-310.
38. Cauwenbergh, G., H. Degreef, J. Heykants, R. Woestenborghs, P. Van Rooy, and K. Haeverans. 1988. Pharmacokinetic profile of orally administered itraconazole in human skin. J. Am. Acad. Dermatol. 18:263-268.
39. Chandra, P., and K. L. Brouwer. 2004. The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. 21:719-735.
40. Chanock, S. 2001. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. Dis. Markers 17:89-98.
41. Chen, C. J., D. Clark, K. Ueda, I. Pastan, M. M. Gottesman, and I. B. Roninson. 1990. Genomic organization of the human multidrug resistance (MDR1) gene and origin of P-glycoproteins. J. Biol. Chem. 265:506-514.
42. Chow, M. S., C. M. White, C. P. Lau, C. Fan, and M. O. Tang. 2001. Evaluation of CYP2D6 oxidation of dextromethorphan and propafenone in a Chinese population with atrial fibrillation. J. Clin. Pharmacol. 41:92-96.
43. Cohen, A. D., E. Medvesovsky, R. Shalev, A. Biton, T. Chetov, S. Naimer, A. Shai, and D. A. Vardy. 2003. An independent comparison of terbinafine and itraconazole in the treatment of toenail onychomycosis. J. Dermatolog. Treat. 14:237-242.
44. Cornford, E. M., C. P. Diep, and W. M. Pardridge. 1985. Blood-brain barrier transport of valproic acid. J. Neurochem. 44:1541-1550.
45. Courtney, R., E. Radwanski, J. Lim, and M. Laughlin. 2004. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother. 48:804-808.
46. Courtney, R., A. Sansone, W. Smith, T. Marbury, P. Statkevich, M. Martinho, M. Laughlin, and S. Swan. 2005. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol. 45:185-192.
47. Courtney, R., D. Wexler, E. Radwanski, J. Lim, and M. Laughlin. 2004. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222.
48. Cribb, A. E., R. Isbrucker, T. Levatte, B. Tsui, C. T. Gillespie, and K. W. Renton. 1994. Acetylator phenotyping: the urinary caffeine metabolite ratio in slow acetylators correlates with a marker of systemic NAT1 activity. Pharmacogenetics 4:166-170.
49. Csajka, C., L. A Decosterd, T. Buclin, J. L. Pagani, K. Fattinger, J. Bille, and J. Biollaz. 2001. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur. J. Clin. Pharmacol. 57:723-727.
50. Daly, A. K. 2003. Candidate gene case-control studies. Pharmacogenomics 4:127-139.
51. Daly, A. K. 2003. Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam. Clin. Pharmacol. 17:27-41.
52. Daly, A. K., and C. P. Day. 2001. Candidate gene case-control association studies: advantages and potential pitfalls. Br. J. Clin. Pharmacol. 52:489-499.
53. Dammerman, M., and J. L. Breslow. 1995. Genetic basis of lipoprotein disorders. Circulation 91:505-512.
54. Daneshmend, T. K., and D. W. Warnock. 1983. Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinet. 8:17-42.
55. Dangi, J. S., S. P. Vyas, and V. K. Dixit. 1998. Effect of various lipid-bile salt mixed micelles on the intestinal absorption of amphotericin-B in rat. Drug Dev. Ind. Pharm. 24:631-635.
56. Dasgupta, A., and M. Luke. 1997. Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor. Ther. Drug Monit. 19:281-285.
57. Dean, R. P. 1994. Food and drug interactions affecting itraconazole absorption. Top. Drug Ther. 36:1-5.
58. De Beule, K., and J. Van Gestel. 2001. Pharmacology of itraconazole. Drugs 61(Suppl. 1):27-37.
59. Debruyne, D. 1997. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses. Clin. Pharmacokinet. 33:52-77.
60. Debruyne, D., and A Coquerel. 2001. Pharmacokinetics of antifungal agents in onychomycoses. Clin. Pharmacokinet. 40:441-412.
61. Debruyne, D., and J. P. Ryckelynck. 1993. Clinical pharmacokinetics of fluconazole. Clin. Pharmacokinet. 24:10-27.
62. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
63. Denning, D. W. 2002. Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. 49:889-891.
64. Denning, D. W., A. Marinus, J. Cohen, D. Spence, R. Herbrecht, L. Pagano, C. Kibbler, V. Kcrmery, F. Offner, C. Cordonnier, U. Jehn, M. Ellis, L. Collette, R. Sylvester, et al. 1998. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. J. Infect. 37:173-180.
65. Deresinski, S. C., and D. A. Stevens. 2003. Caspofungin. Clin. Infect. Dis. 36:1445-1457.
66. Desta, Z., X. Zhao, J. G. Shin, and D. A. Flockhart. 2002. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41:913-958.
67. Diebold, K., G. Michel, J. Schweizer, M. Diebold-Dorsam, W. Fiehn, and B. Kohl. 1998. Are psychoactive-drug-induced changes in plasma lipid and lipoprotein levels of significance for clinical remission in psychiatric disorders? Pharmacopsychiatry 31:60-67.
68. Donato, M. T., and J. V. Castell. 2003. Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. Clin. Pharmacokinet. 42:153-178.
69. Dowell, J. A., W. Knebel, T. Ludden, M. Stogniew, D. Krause, and T. Henkel. 2004. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J. Clin. Pharmacol. 44:590-598.
70. Duan, J., M. S. Wainwright, J. M. Comeron, N. Saitou, A. R. Sanders, J. Gelernter, and P. V. Gejman. 2003. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12:205-216.
71. Dursun, S. M., A. Szemis, H. Andrews, and M. A. Reveley. 1999. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J. Psychiatry Neurosci. 24:453-455.
72. Ehrnebo, M., S. Agurell, B. Jalling, and L. O. Boreus. 1971. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur. J. Clin. Pharmacol. 3:189-193.
73. Ekins, S., and S. A. Wrighton. 1999. The role of CYP2B6 in human xenobiotic metabolism. Drug Metab. Rev. 31:719-754.
74. Ernst, E. J. 2001. Investigational antifungal agents. Pharmacotherapy 21:165S-174S.
75. Evans, W. E., and H. L. McLeod. 2003. Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348:538-549.
76. Faergemann, J., H. Zehender, T. Jones, and I. Maibach. 1991. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm. Venereol. 71:322-326.
77. Fanos, V., and L. Cataldi. 2001. Renal transport of antibiotics and nephrotoxicity: a review. J. Chemother. 13:461-472.
78. FDA Antiviral Advisory Committee. 4 October 2001. Briefing document for voriconazole (oral and intravenous formulations). [Online.] http://www.fda .gov/ohrms/dockets/ac/01/briefing/3792b2_01_Pfizer.pdf.
79. Feinberg, A. P., and B. Tycko. 2004. The history of cancer epigenetics. Nat. Rev. Cancer 4:143-153.
80. Fellay, J., C. Marzolini, E. R. Meaden, D. J. Back, T. Buclin, J. P. Chave, L. A. Decosterd, H. Furrer, M. Opravil, G. Pantaleo, D. Retelska, L. Ruiz, A. H. Schinkel, P. Vernazza, C. B. Eap, and A. Telenti. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
81. Finta, C., and P. G. Zaphiropoulos. 2002. Intergenic mRNA molecules resulting from trans-splicing. J. Biol. Chem. 277:5882-5890.
82. Force, R. W., and M. C. Nahata. 1995. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. Ann. Pharmacother. 29:10-15.
83. Franco, M. H., S. O. Brennan, E. K. Chua, U. Kragh-Hansen, S. M. Callegari-Jacques, M. Z. Bezerra, and F. M. Salzano. 1999. Albumin genetic variability in South America: population distribution and molecular studies. Am. J. Hum. Biol. 11:359-366.
84. Freedman, M. L., D. Reich, K. L. Penney, G. J. McDonald, A. A. Mignault, N. Patterson, S. B. Gabriel, E. J. Topol, J. W. Smoller, C. N. Pato, M. T. Pato, T. L. Petryshen, L. N. Kolonel, E. S. Lander, P. Sklar, B. Henderson, J. N. Hirschhorn, and D. Altshuler. 2004. Assessing the impact of population stratification on genetic association studies. Nat. Genet. 36:388-393.
85. Fromm, M. F. 2000. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38:69-74.
86. Fromm, M. F. 2002. The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. Adv. Drug Deliv. Rev. 54:1295-1310.
87. Fromtling, R. A. 2002. Micafungin sodium (FK-463). Drugs Today 38:245-257.
88. Furuta, T., K. Ohashi, T. Kamata, M. Takashima, K. Kosuge, T. Kawasaki, H. Hanai, T. Kubota, T. Ishizaki, and E. Kaneko. 1998. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann. Intern. Med. 129:1027-1030.
89. Gabriel, S. B., S. F. Schaffner, H. Nguyen, J. M. Moore, J. Roy, B. Blumenstiel, J. Higgins, M. DeFelice, A. Lochner, M. Faggart, S. N. Liu-Cordero, C. Rotimi, A. Adeyemo, R. Cooper, R. Ward, E. S. Lander, M. J. Daly, and D. Altshuler. 2002. The structure of haplotype blocks in the human genome. Science 296:2225-2229.
90. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
91. Garcia, C. K., G. Mues, Y. Liao, T. Hyatt, N. Patil, J. C. Cohen, and H. H. Hobbs. 2001. Sequence diversity in genes of lipid metabolism. Genome Res. 11:1043-1052.
92. Gaudry, S. E., D. S. Sitar, D. D. Smyth, J. K. McKenzie, and F. Y. Aoki. 1993. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin. Pharmacol. Ther. 54:23-27.
93. Ghannoum, M. A., and D. M. Kuhn. 2002. Voriconazole-better chances for patients with invasive mycoses. Eur. J. Med. Res. 7:242-256.
94. Ghosal, A., N. Hapangama, Y. Yuan, J. Achanfuo-Yeboah, R. Iannucci, S. Chowdhury, K. Alton, J. E. Patrick, and S. Zbaida. 2004. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab. Dispos. 32:267-271.
95. Ginsberg, H. N. 1998. Lipoprotein physiology. Endocrinol. Metab. Clin. N. Am. 27:503-519.
96. Goldstein, J. A. 2001. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol. 52:349-355.
97. Greenblatt, D. J., E. M. Sellers, and R. I. Shader. 1982. Drug therapy: drug disposition in old age. N. Engl. J. Med. 306:1081-1088.
98. Groll, A. H., J. C. Gea-Banacloche, A. Glasmacher, G. Just-Nuebling, G. Maschmeyer, and T. J. Walsh. 2003. Clinical pharmacology of antifungal compounds. Infect. Dis. Clin. N. Am. 17:159-191, ix.
99. Groll, A. H., N. Giri, V. Petraitis, R. Petraitiene, M. Candelario, J. S. Bacher, S. C. Piscitelli, and T. J. Walsh. 2000. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. J. Infect. Dis. 182:274-282.
100. Groll, A. H., D. Mickiene, V. Petraitis, R. Petraitiene, K. H. Ibrahim, S. C. Piscitelli, I. Bekersky, and T. J. Walsh. 2001. Compartmental pharmacokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrob. Agents Chemother. 45:3322-3327.
101. Groll, A. H., S. C. Piscitelli, and T. J. Walsh. 1998. Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development. Adv. Pharmacol. 44:343-500.
102. Groll, A. H., and T. J. Walsh. 2001. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Exp. Opin. Investig. Drugs 10:1545-1558.
103. Groll, A. H., L. Wood, M. Roden, D. Mickiene, C. C. Chiou, E. Townley, L. Dad, S. C. Piscitelli, and T. J. Walsh. 2002. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob. Agents Chemother. 46:2554-2563.
104. Grossi, P., C. Farina, R. Fiocchi, and D. Dalla Gasperina, et al. 2000. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Transplantation 70:112-116.
105. Guillemette, C. 2003. Pharmacogenomics of human UDP- glucuronosyltransferase enzymes. Pharmacogenomics J. 3:136-158.
106. Gwilt, P. R., R. R. Nahhas, and W. G. Tracewell. 1991. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin. Pharmacokinet. 20:477-490.
107. Hagenbuch, B., and P. J. Meier. 2003. The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609:1-18.
108. Hajdu, R., R. Thompson, J. G. Sundelof, B. A. Pelak, F. A. Bouffard, J. F. Dropinski, and H. Kropp. 1997. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. 41:2339-2344.
109. Hartsel, S. C., B. Baas, E. Bauer, L. T. Foree, Jr., K. Kindt, H. Preis, A. Scott, E. H. Kwong, M. Ramaswamy, and K. M. Wasan. 2001. Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha. J. Pharm. Sci. 90:124-133.
110. Hasler, J. A. 1999. Pharmacogenetics of cytochromes P450. Mol. Aspects Med. 20:12-24, 25-137.
111. Hebert, M. F., H. E. Smith, T. C. Marbury, S. K. Swan, W. B. Smith, R. W. Townsend, D. Buell, J. Keirns, and I. Bekersky. 2005. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. J. Clin. Pharmacol. 45:1145-1152.
112. Heft, M. W., and A. J. Mariotti. 2002. Geriatric pharmacology. Dent. Clin. N. Am. 46:869-885, xii.
113. Hegele, R. A. 1997. Small genetic effects in complex diseases: a review of regulatory sequence variants in dyslipoproteinemia and atherosclerosis. Clin. Biochem. 30:183-188.
114. Hein, D. W. 2002. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat. Res. 506-507:65-77.
115. Hein, D. W., M. A. Doll, A. J. Fretland, M. A. Leff, S. J. Webb, G. H. Xiao, U. S. Devanaboyina, N. A. Nangju, and Y. Feng. 2000. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomarkers Prev. 9:29-42.
116. Heykants, J., A. Van Peer, V. Van de Velde, P. Van Rooy, W. Meuldermans, K. Lavrijsen, R. Woestenborghs, J. Van Cutsem, and G. Cauwenbergh. 1989. The clinical pharmacokinetics of itraconazole: an overview. Mycoses 32(Suppl. 1):67-87.
117. Hiemenz, J. W., and T. J. Walsh. 1996. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2): S133-S144.
118. Hinoshita, E., K. Taguchi, A. Inokuchi, T. Uchiumi, N. Kinukawa, M. Shimada, M. Tsuneyoshi, K. Sugimachi, and M. Kuwano. 2001. Decreased expression of an ATP-binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. J. Hepatol. 35:765-773.
119. -1) for onychomycosis. Evaluation of treatment results according to patient background. Mycoses 44:87-93.
120. Hoffman, H. L., E. J. Ernst, and M. E. Klepser. 2000. Novel triazole antifungal agents. Exp. Opin. Investig. Drugs. 9:593-605.
121. Hoffman, H. L., and R. C. Rathbun. 2002. Review of the safety and efficacy of voriconazole. Exp. Opin. Investig. Drugs 11:409-429.
122. Hoffmeyer, S., O. Burk, O. von Richter, H. P. Arnold, J. Brockmoller, A. Johne, I. Cascorbi, T. Gerloff, I. Roots, M. Eichelbaum, and U. Brinkmann. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 97:3473-3478.
123. Hossain, M. A., and M. A. Ghannoum. 2000. New investigational antifungal agents for treating invasive fungal infections. Exp. Opin. Investig. Drugs 9:1797-1813.
124. Hosseini-Yeganeh, M., and A. J. McLachlan. 2001. Tissue distribution of terbinafine in rats. J. Pharm. Sci. 90:1817-1828.
125. Hu, Y., M. Oscarson, I. Johansson, Q. Y. Yue, M. L. Dahl, M. Tabone, S. Arinco, E. Albano, and M. Ingelman-Sundberg. 1997. Genetic polymorphism of human CYP2E1: characterization of two variant alleles. Mol. Pharmacol. 51:370-376.
126. Hughes, A. L., B. Packer, R. Welch, A. W. Bergen, S. J. Chanock, and M. Yeager. 2003. Widespread purifying selection at polymorphic sites in human protein-coding loci. Proc. Natl. Acad. Sci. USA 100:15754-15757.
127. Humbert, H., J. Denouel, M. D. Cabiac, H. Lakhdar, and A. Sioufi. 1998. Pharmacokinetics of terbinafine and five known metabolites in children, after oral administration. Biopharm. Drug Dispos. 19:417-423.
128. Hyland, R., B. C. Jones, and D. A. Smith. 2003. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab. Dispos. 31:540-547.
129. Iida, N., K. Takara, N. Ohmoto, T. Nakamura, T. Kimura, A. Wada, M. Hirai, T. Sakaeda, and K. Okumura. 2001. Reversal effects of antifungal drugs on multidrug resistance in MDR1-overexpressing HeLa cells. Biol. Pharm. Bull. 24:1032-1036.
130. Imbert, F., M. Jardin, C. Fernandez, J. C. Gantier, F. Dromer, G. Baron, F. Mentre, L. Van Beijsterveldt, E. Singlas, and F. Gimenez. 2003. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans. Drug Metab. Dispos. 31:319-325.
131. Reference deleted.
132. Ingelman-Sundberg, M. 2001. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med. 250:186-200.
133. Israili, Z. H., and P. G. Dayton. 2001. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33:161-235.
134. Jain, S., and V. N. Sehgal. 2000. Terbinafine, a unique oral antifungal: current perceptions. Int. J. Dermatol. 39:412-423.
135. Jezequel, S. G. 1994. Fluconazole: interspecies scaling and allometric relationships of pharmacokinetic properties. J. Pharm. Pharmacol. 46:196-199.
136. Johnson, J. A., and T. N. Livingston. 1997. Differences between blacks and whites in plasma protein binding of drugs. Eur. J. Clin. Pharmacol. 51:485-488.
137. Johnson, L. B., and C. A. Kauffman. 2003. Voriconazole: a new triazole antifungal agent. Clin. Infect. Dis. 36:630-637.
138. Jolliet-Riant, P., M. F. Boukef, J. C. Duche, N. Simon, and J. P. Tillement. 1998. The genetic variant A of human alpha 1-acid glycoprotein limits the blood to brain transfer of drugs it binds. Life Sci. 62:PL219-PL226.
139. Kartenbeck, J., U. Leuschner, R. Mayer, and D. Keppler. 1996. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 23:1061-1066.
140. Kearns, G. L., S. M. Abdel-Rahman, S. W. Alander, D. L. Blowey, J. S. Leeder, and R. E. Kauffman. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157-1167.
141. Keitel, V., J. Kartenbeck, A. T. Nies, H. Spring, M. Brom, and D. Keppler. 2000. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 32:1317-1328.
142. Kennedy, A. L., and K. M. Wasan. 1999. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. J. Pharm. Sci. 88:1149-1155.
143. Kim, R. B. 2002. Transporters and xenobiotic disposition. Toxicology 181-182:291-297.
144. Kim, R. B., B. F. Leake, E. F. Choo, G. K. Dresser, S. V. Kubba, U. I. Schwarz, A. Taylor, H. G. Xie, J. McKinsey, S. Zhou, L. B. Lan, J. D. Schuetz, E. G. Schuetz, and G. R. Wilkinson. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 70:189-199.
145. Kishino, S., A. Nomura, Z. S. Di, M. Sugawara, K. Iseki, S. Kakinoki, A. Kitabatake, and K. Miyazaki. 1995. Alpha-1-acid glycoprotein concentration and the protein binding of disopyramide in healthy subjects. J. Clin. Pharmacol. 35:510-514.
146. Knoblauch, H., A. Bauerfeind, C. Krahenbuhl, A. Daury, K. Rohde, S. Bejanin, L. Essioux, H. Schuster, F. C. Luft, and J. G. Reich. 2002. Common haplotypes in five genes influence genetic variance of LDL and HDL cholesterol in the general population. Hum. Mol. Genet. 11:1477-1485.
147. Konig, J., D. Rost, Y. Cui, and D. Keppler. 1999. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. Hepatology 29:1156-1163.
148. Kontoyiannis, D. P., and R. E. Lewis. 2002. Antifungal drug resistance of pathogenic fungi. Lancet 359:1135-1144.
149. Kragh-Hansen, U., S. O. Brennan, M. Galliano, and O. Sugita. 1990. Binding of warfarin, salicylate, and diazepam to genetic variants of human serum albumin with known mutations. Mol. Pharmacol. 37:238-242.
150. Kragh-Hansen, U., V. T. Chuang, and M. Otagiri. 2002. Practical aspects of the ligand-binding and enzymatic properties of human serum albumin. Biol. Pharm. Bull. 25:695-704.
151. Krieter, P., B. Flannery, T. Musick, M. Gohdes, M. Martinho, and R. Courtney. 2004. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother. 48:3543-3551.
152. Kruglyak, L., and D. A. Nickerson. 2001. Variation is the spice of life. Nat. Genet. 27:234-236.
153. Kruijtzer, C. M., J. H. Beijnen, and J. H. Schellens. 2002. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. Oncologist 7:516-530.
154. Kuehl, P., J. Zhang, Y. Lin, J. Lamba, M. Assem, J. Schuetz, P. B. Watkins, A. Daly, S. A. Wrighton, S. D. Hall, P. Maurel, M. Relling, C. Brimer, K. Yasuda, R. Venkataramanan, S. Strom, K. Thummel, M. S. Boguski, and E. Schuetz. 2001. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27:383-391.
155. Kusuhara, H., and Y. Sugiyama. 2002. Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney. J. Control Release 78:43-54.
156. Kwong, M., and K. M. Wasan. 2002. Cholesteryl ester transfer protein facilitates the movement of water-insoluble drugs between lipoproteins: a novel biological function for a well-characterized lipid transfer protein. Biochem. Pharmacol. 64:1669-1675.
157. Lamba, J. K., Y. S. Lin, E. G. Schuetz, and K. E. Thummel. 2002. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54:1271-1294.
158. Lang, T., K. Klein, J. Fischer, A. K. Nussler, P. Neuhaus, U. Hofmann, M. Eichelbaum, M. Schwab, and U. M. Zanger. 2001. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
159. Lazar, J. D., and K. D. Wilner. 1990. Drug interactions with fluconazole. Rev. Infect. Dis. 12(Suppl. 3):S327-S333.
160. Leabman, M. K., C. C. Huang, M. Kawamoto, S. J. Johns, D. Stryke, T. E. Ferrin, J. DeYoung, T. Taylor, A. G. Clark, I. Herskowitz, and K. M. Giacomini. 2002. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12:395-405.
161. Lee, C. H., P. H. Yeh, and T. H. Tsai. 2002. Hepatobiliary excretion of fluconazole and its interaction with cyclosporin A in rat blood and bile using microdialysis. Int. J. Pharm. 241:367-373.
162. Lee, C. R., J. A. Goldstein, and J. A. Pieper. 2002. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251-263.
163. Lee, J. W., N. L. Seibel, M. Amantea, P. Whitcomb, P. A. Pizzo, and T. J. Walsh. 1992. Safety and pharmacokinetics of fluconazole in children with neoplastic diseases. J. Pediatr. 120:987-993.
164. Lee, W., and R. B. Kim. 2004. Transporters and renal drug elimination. Annu. Rev. Pharmacol. Toxicol. 44:137-166.
165. Lelawongs, P., J. A. Barone, J. L. Colaizzi, A. T. Hsuan, W. Mechlinski, R. Legendre, and J. Guarnieri. 1988. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin. Pharm. 7:228-235.
166. Li, J. H., J. Q. Xu, X. M. Cao, L. Ni, Y. Li, Y. Y. Zhuang, and J. B. Gong. 2002. Influence of the ORM1 phenotypes on serum unbound concentration and protein binding of quinidine. Clin. Chim. Acta 317:85-92.
167. Lin, J. H., M. Chiba, and T. A. Baillie. 1999. Is the role of the small intestine in first pass metabolism overemphasized? Pharmacol. Rev. 51:135-158.
168. Lin, J. H., and M. Yamazaki. 2003. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 42:59-98.
169. Lovich, M. A., C. Creel, K. Hong, C. W. Hwang, and E. R. Edelman. 2001. Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. J. Pharm. Sci. 90:1324-1335.
170. Lown, K. S., R. R. Mayo, A. B. Leichtman, H. L. Hsiao, D. K. Turgeon, P. Schmiedlin-Ren, M. B. Brown, W. Guo, S. J. Rossi, L. Z. Benet, and P. B. Watkins. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin. Pharmacol. Ther. 62:248-260.
171. Lyman, C. A., and T. J. Walsh. 1992. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44:9-35.
172. Ma, M. K., M. H. Woo, and H. L. McLeod. 2002. Genetic basis of drug
173. MacCallum, D. M., and F. C. Odds. 2002. Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. J. Antimicrob. Chemother. 50:219-224.
174. Machard, B., P. Misslin, and M. Lemaire. 1989. Influence of plasma protein binding on the brain uptake of an antifungal agent, terbinafine, in rats. J. Pharm. Pharmacol. 41:700-704.
175. Madison, J., M. Galliano, S. Watkins, L. Minchiotti, F. Porta, A. Rossi, and F. W. Putnam. 1994. Genetic variants of human serum albumin in Italy: point mutants and a carboxyl-terminal variant. Proc. Natl. Acad. Sci. USA 91:6476-6480.
176. Marchini, J., L. R. Cardon, M. S. Phillips, and P. Donnelly. 2004. The effects of human population structure on large genetic association studies. Nat. Genet. 36:512-517.
177. Martinez-Jorda, R., J. M. Rodriguez-Sasiain, E. Suarez, and R. Calvo. 1990. Serum binding of ketoconazole in health and disease. Int. J. Clin. Pharmacol. Res. 10:271-276.
178. Masereeuw, R., and F. G. Russel. 2001. Mechanisms and clinical implications of renal drug excretion. Drug Metab. Rev. 33:299-351.
179. May, D. B., R. H. Drew, K. C. Yedinak, and J. A. Bartlett. 1994. Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers. Pharmacotherapy 14:509-513.
180. McCarthy, J. J., and R. Hilfiker. 2000. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat. Biotechnol. 18:505-508.
181. McLeod, H. L., and W. E. Evans. 2001. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41:101-121.
182. McLeod, H. L., and C. Siva. 2002. The thiopurine S-methyltransferase gene locus-implications for clinical pharmacogenomics. Pharmacogenomics 3:89-98.
183. McLeod, H. L., and J. Yu. 2003. Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Invest. 21:630-640.
184. Meibohm, B., I. Beierle, and H. Derendorf. 2002. How important are gender differences in pharmacokinetics? Clin. Pharmacokinet. 41:329-342.
185. Meyer, J. C., C. Burri, P. Ruf, and U. W. Schnyder. 1989. Factors affecting plasma levels of ketoconazole during long-term treatment. Dermatologica 178:29-32.
186. Milne, R. W., L. A. Larsen, K. L. Jorgensen, J. Bastlund, G. R. Stretch, and A. M. Evans. 2000. Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. Pharm. Res. 17:1511-1515.
187. Miyama, T., H. Takanaga, H. Matsuo, K. Yamano, K. Yamamoto, T. Iga, M. Naito, T. Tsuruo, H. Ishizuka, Y. Kawahara, and Y. Sawada. 1998. P-glycoprotein-mediated transport of itraconazole across the blood-brain barrier. Antimicrob. Agents Chemother. 42:1738-1744.
188. Mor-Cohen, R., A. Zivelin, N. Rosenberg, M. Shani, S. Muallem, and U. Seligsohn. 2001. Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J. Biol. Chem. 276:36923-36930.
189. Moretti, M. E., S. Ito, and G. Koren. 1995. Disposition of maternal ketoconazole in breast milk. Am. J. Obstet. Gynecol. 173:1625-1626.
190. Morrison, V. A., R. J. Haake, and D. J. Weisdorf. 1994. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am. J. Med. 96:497-503.
191. Nagata, K., and Y. Yamazoe. 2000. Pharmacogenetics of sulfotransferase. Annu. Rev. Pharmacol. Toxicol. 40:159-176.
192. Nath, C. E., A. J. McLachlan, P. J. Shaw, R. Gunning, and J. W. Earl. 2001. Population pharmacokinetics of amphotericin B in children with malignant diseases. Br. J. Clin. Pharmacol. 52:671-680.
193. Nedelman, J., J. A. Cramer, B. Robbins, E. Gibiansky, C. T. Chang, S. Gareffa, A. Cohen, and J. Meligeni. 1997. The effect of food on the pharmacokinetics of multiple dose terbinafine in young and elderly healthy subjects. Biopharm. Drug Dispos. 18:127-138.
194. Nejjam, F., M. Zagula, M. D. Cabiac, N. Guessous, H. Humbert, and H. Lakhdar. 1995. Pilot study of terbinafine in children suffering from tinea capitis: evaluation of efficacy, safety and pharmacokinetics. Br. J. Dermatol. 132:98-105.
195. Neuvonen, P. J., and K. M. Jalava. 1996. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 60:54-61.
196. Nishihara, K., J. Hibino, H. Kotaki, Y. Sawada, and T. Iga. 1999. Effect of itraconazole on the pharmacokinetics of digoxin in guinea pigs. Biopharm. Drug Dispos. 20:145-149.
197. Norton, R. M. 2001. Clinical pharmacogenomics: applications in pharmaceutical R&D. Drug Discov. Today 6:180-185.
198. Nozawa, T., M. Nakajima, I. Tamai, K. Noda, J. Nezu, Y. Sai, A. Tsuji, and T. Yokoi. 2002. Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302:804-813.
199. Olbe, L., E. Carlsson, and P. Lindberg. 2003. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat. Rev. Drug Discov. 2:132-139.
200. Persson, K., S. Sjostrom, I. Sigurdardottir, V. Molnar, M. Hammarlund-Udenaes, and A. Rane. 1995. Patient-controlled analgesia (PCA) with codeine for postoperative pain relief in ten extensive metabolisers and one poor metaboliser of dextromethorphan. Br. J. Clin. Pharmacol. 39:182-186.
201. Petersen, C. E., C. E. Ha, K. Harohalli, D. S. Park, and N. V. Bhagavan. 2000. Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics. Chem. Biol. Interact. 124:161-172.
202. Petraitis, V., R. Petraitiene, A. H. Groll, T. Sein, R. L. Schaufele, C. A. Lyman, A. Francesconi, J. Bacher, S. C. Piscitelli, and T. J. Walsh. 2001. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis. Antimicrob. Agents Chemother. 45:471-479.
203. Pollock, B. G. 1997. Gender differences in psychotropic drug metabolism. Psychopharmacol. Bull. 33:235-241.
204. Prentice, A. G., and P. Donnelly. 2001. Oral antifungals as prophylaxis in haematological malignancy. Blood Rev. 15:1-8.
205. Pritchard, J. K., M. Stephens, N. A, Rosenberg, and P. Donnelly. 2000. Association mapping in structured populations. Am. J. Hum. Genet. 67:170-181.
206. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
207. Purkins, L., N. Wood, D. Kleinermans, K. Greenhalgh, and D. Nichols. 2003. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br. J. Clin. Pharmacol. 56(Suppl. 1):17-23.
208. Ramaswamy, M., K. D. Peteherych, A. L. Kennedy, and K. M. Wasan. 2001. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob. Agents Chemother. 45:1184-1191.
209. Raunio, H., A. Rautio, H. Gullsten, and O. Pelkonen. 2001. Polymorphisms of CYP2A6 and its practical consequences. Br. J. Clin. Pharmacol. 52:357-363.
210. Reed, R. G., and C. M. Burrington. 1989. The albumin receptor effect may be due to a surface-induced conformational change in albumin. J. Biol. Chem. 264:9867-9872.
211. Reynes, J., C. Bazin, F. Ajana, A. Datry, J. P. Le Moing, E. Chwetzoff, and J. C. Levron. 1997. Pharmacokinetics of itraconazole (oral solution) in two groups of human immunodeficiency virus-infected adults with oral candidiasis. Antimicrob. Agents Chemother. 41:2554-2558.
212. Rheney, C. C., and C. M. Saddler. 1998. Oral ketoconazole in cutaneous fungal infections. Ann. Pharmacother. 32:709-711.
213. Rioux, P. P. 2000. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am. J. Health Syst. Pharm. 57:887-898.
214. Risch, N. J. 2000. Searching for genetic determinants in the new millennium. Nature 405:847-856.
215. Rogers, J. F., A. N. Nafziger, and J. S. Bertino, Jr. 2002. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med. 113:746-750.
216. Romanini, D., G. Avalle, B. Farruggia, B. Nerli, and G. Pico. 1998. Spectroscopy features of the binding of polyene antibiotics to human serum albumin. Chem. Biol. Interact. 115:247-260.
217. Romanini, D., G. Muller, and G. Pico. 2002. Use of amphotericin B as optical probe to study conformational changes and thermodynamic stability in human serum albumin. J. Protein Chem. 21:505-514.
218. Ryder, N. S., and I. Frank. 1992. Interaction of terbinafine with human serum and serum proteins. J. Med. Vet. Mycol. 30:451-460.
219. Sachidanandam, R., D. Weissman, S. C. Schmidt, J. M. Kakol, L. D. Stein, G. Marth, S. Sherry, J. C. Mullikin, B. J. Mortimore, D. L. Willey, S. E. Hunt, C. G. Cole, P. C. Coggill, C. M. Rice, Z. Ning, J. Rogers, D. R. Bentley, P. Y. Kwok, E. R. Mardis, R. T. Yeh, B. Schultz, L. Cook, R. Davenport, M. Dante, L. Fulton, L. Hillier, R. H. Waterston, J. D. McPherson, B. Gilman, S. Schaffner, W. J. Van Etten, D. Reich, J. Higgins, M. J. Daly, B. Blumenstiel, J. Baldwin, N. Stange-Thomann, M. C. Zody, L. Linton, E. S. Lander, and D. Altshuler. 2001. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933.
220. Sakaeda, T., T. Nakamura, M. Horinouchi, M. Kakumoto, N. Ohmoto, T. Sakai, Y. Morita, T. Tamura, N. Aoyama, M. Hirai, M. Kasuga, and K. Okumura. 2001. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 18:1400-1404.
221. Salisbury, B. A., M. Pungliya, J. Y. Choi, R. Jiang, X. J. Sun, and J. C. Stephens. 2003. SNP and haplotype variation in the human genome. Mutat. Res. 526:53-61.
222. Sandhu, P., W. Lee, X. Xu, B. F. Leake, M. Yamazaki, J. A. Stone, J. H. Lin, P. G. Pearson, and R. B. Kim. 2005. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab. Dispos. 33:676-682.
223. Sanglard, D., F. Ischer, M. Monod, and J. Bille. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother. 40:2300-2305.
224. Schafer-Korting, M. 1993. Pharmacokinetic optimisation of oral antifungal therapy. Clin. Pharmacokinet. 25:329-341.
225. Schafer-Korting, M., H. C. Korting, W. Rittler, and W. Obermuller. 1995. Influence of serum protein binding on the in vitro activity of anti-fungal agents. Infection 23:292-297.
226. Schinkel, A. H., and J. W. Jonker. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55:3-29.
227. Schmidt, L. E., and K. Dal hoff. 2002. Food-drug interactions. Drugs 62:1481-1502.
228. Schuetzer-Muehlbauer, M., B. Willinger, G. Krapf, S. Enzinger, E. Presterl, and K. Kuchler. 2003. The Candida albicans Cdr2p ATP-binding cassette (ABC) transporter confers resistance to caspofungin. Mol. Microbiol. 48:225-235.
229. Schwab, M., M. Eichelbaum, and M. F. Fromm. 2003. Genetic polymorphisms of the human mdr1 drug transporter. Annu. Rev. Pharmacol. Toxicol. 43:285-307.
230. Seidegard, J., W. R. Vorachek, R. W. Pero, and W. R. Pearson. 1988. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc. Natl. Acad. Sci. USA 85:7293-7297.
231. Reference deleted.
232. Shargel, L., and A. Yu. 1999. Applied biopharmaceuticals and pharmacokinetics, 4th ed. Appleton & Lange, Stamford, Conn.
233. Shield, A. J., B. A. Thomae, B. W. Eckloff, E. D. Wieben, and R. M. Weinshilboum. 2004. Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol. Psychiatry 9:151-160.
234. Siber, G. R., P. Echeverria, A. L. Smith, J. W. Paisley, and D. H. Smith. 1975. Pharmacokinetics of gentamicin in children and adults. J. Infect. Dis. 132:637-651.
235. Silverman, J. A. 1999. Multidrug-resistance transporters. Pharm. Biotechnol. 12:353-386.
236. Smit, J. W., A. H. Schinkel, M. Muller, B. Weert, and D. K. Meijer. 1998. Contribution of the murine mdr1a P-glycoprotein to hepatobiliary and intestinal elimination of cationic drugs as measured in mice with an mdr1a gene disruption. Hepatology 27:1056-1063.
237. Smit, J. W., A. H. Schinkel, B. Weert, and D. K. Meyer. 1998. Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. Br. J. Pharmacol. 124:416-424.
238. Soyama, A., N. Hanioka, Y. Saito, N. Murayama, M. Ando, S. Ozawa, and J. Sawada. 2002. Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacol. Toxicol. 91:174-178.
239. Soyama, A., Y. Saito, N. Hanioka, N. Murayama, O. Nakajima, N. Katori, S. Ishida, K. Sai, S. Ozawa, and J. I. Sawada. 2001. Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol. Pharm. Bull. 24:1427-1430.
240. Spielberg, S. P. 1996. N-Acetyltransferases: pharmacogenetics and clinical consequences of polymorphic drug metabolism. J. Pharmacokinet. Biopharm. 24:509-519.
241. Spielman, R. S., and W. J. Ewens. 1996. The TDT and other family-based tests for linkage disequilibrium and association. Am. J. Hum. Genet. 59:983-989.
242. Starke, J. R., E. O. Mason, Jr., W. G. Kramer, and S. L. Kaplan. 1987. Pharmacokinetics of amphotericin B in infants and children. J. Infect. Dis. 155:766-774.
243. Stein, R. S., K. Albridge, R. K. Lenox, W. Ray, and J. M. Flexner. 1988. Nephrotoxicity in leukemic patients receiving empirical amphotericin B and aminoglycosides. South. Med. J. 81:1095-1099.
244. Stone, E. A., H. B. Fung, and H. L. Kirschenbaum. 2002. Caspofungin: an echinocandin antifungal agent. Clin. Ther. 24:351-377.
245. Stone, J. A., E. M. Migoya, L. Hickey, G. A. Winchell, P. J. Deutsch, K. Ghosh, A. Freeman, S. Bi, R. Desai, S. C. Dilzer, K. C. Lasseter, W. K. Kraft, H. Greenberg, and S. A. Waldman. 2004. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob. Agents Chemother. 48:4306-4314.
246. Stracham, T., and P. R. Andrew. 1999. Human molecular genetics, 2nd ed. John Wiley & Sons Inc., New York, N.Y.
247. Sugar, A. M., and X. P. Liu. 2000. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med. Mycol. 38:209-212.
248. Sun, H., H. Dai, N. Shaik, and W. F. Elmquist. 2003. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 55:83-105.
249. Suzuki, H., and Y. Sugiyama. 2002. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 54:1311-1331.
250. Talwalkar, J. A., R. E. Soetikno, D. L. Carr-Locke, and C. L. Berg. 1999. Severe cholestasis related to intraconazole for the treatment of onychomycosis. Am. J. Gastroenterol. 94:3632-3633.
251. Taylor, J. G., E. H. Choi, C. B. Foster, and S. J. Chanock. 2001. Using genetic variation to study human disease. Trends Mol. Med. 7:507-512.
252. Tirona, R. G., B. F. Leake, G. Merino, and R. B. Kim. 2001. Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J. Biol. Chem. 276:35669-35675.
253. Tsai, Y. J., and H. E. Hoyme. 2002. Pharmacogenomics: the future of drug therapy. Clin. Genet. 62:257-264.
254. Tsuji, A., and I. Tamai. 1996. Carrier-mediated intestinal transport of drugs. Pharm. Res. 13:963-977.
255. Vadiei, K., G. Lopez-Berestein, and D. R. Luke. 1990. Disposition and toxicity of amphotericin-B in the hyperlipidemic Zucker rat model. Int. J. Obes. 14:465-472.
256. Van Aubel, R. A., R. Masereeuw, and F. G. Russel. 2000. Molecular pharmacology of renal organic anion transporters. Am. J. Physiol. Renal Physiol. 279:F216-F232.
257. Van Bambeke, F., J. M. Michot, and P. M. Tulkens. 2003. Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. J. Antimicrob. Chemother. 51:1067-1077.
258. Van Der Meer, J. W., J. J. Keuning, H. W. Scheijgrond, J. Heykants, J. Van Cutsem, and J. Brugmans. 1980. The influence of gastric acidity on the bio-availability of ketoconazole. J. Antimicrob. Chemother. 6:552-554.
259. Vermes, A., H. J. Guchelaar, and J. Dankert. 2000. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J. Antimicrob. Chemother. 46:171-179.
260. Vestberg, K., M. Galliano, L. Minchiotti, and U. Kragh-Hansen. 1992. High-affinity binding of warfarin, salicylate and diazepam to natural mutants of human serum albumin modified in the C-terminal end. Biochem. Pharmacol. 44:1515-1521.
261. Vickers, A. E., J. R. Sinclair, M. Zollinger, F. Heitz, U. Glanzel, L. Johanson, and V. Fischer. 1999. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions. Drug Metab. Dispos. 27:1029-1038.
262. Vincent, S, R. Planells, C. Defoort, M. C. Bernard, M. Gerber, J. Prudhomme, P. Vague, and D. Lairon. 2002. Genetic polymorphisms and lipoprotein responses to diets. Proc. Nutr. Soc. 61:427-434.
263. Wacholder, S., S. Chanock, M. Garcia-Closas, L. El Ghormli, and N. Rothman. 2004. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J. Natl. Cancer Inst. 96:434-442.
264. Wacholder, S., N. Rothman, and N. Caporaso. 2000. Population stratification in epidemiologic studies of common genetic variants and cancer: quantification of bias. J. Natl. Cancer Inst. 92:1151-1158.
265. Walsh, T. J., P. C. Adamson, N. L. Seibel, P. M. Flynn, M. N. Neely, C. Schwartz, A. Shad, S. L. Kaplan, M. M. Roden, J. A. Stone, A. Miller, S. K. Bradshaw, S. X. Li, C. A. Sable, and N. A. Kartsonis. 2005. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob. Agents Chemother. 49:4536-4545.
266. Walsh, T. J., P. Whitcomb, S. Piscitelli, W. D. Figg, S. Hill, S. J. Chanock, P. Jarosinski, R. Gupta, and P. A. Pizzo. 1997. Safety, tolerance, and pharmacokinetics of amphotericin B lipid complex in children with hepatosplenic candidiasis. Antimicrob. Agents Chemother. 41:1944-1948.
267. Wang, E. J., K. Lew, C. N. Casciano, R. P. Clement, and W. W. Johnson. 2002. Interaction of common azole antifungals with P glycoprotein. Antimicrob. Agents Chemother. 46:160-165.
268. Wasan, K. M. 1996. Modifications in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drags. J. Pharmacol. Toxicol. Methods 36:1-11.
269. Wasan, K. M., and S. M. Cassidy. 1998. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87:411-424.
270. Wasan, K. M., A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J. W. Chou, and P. H. Pritchard. 1998. Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies. Antimicrob. Agents Chemother. 42:3146-3152.
271. Wasan, K. M., M. Ramaswamy, S. M. Cassidy, M. Kazemi, F. W. Strobel, and R. L. Thies. 1997. Physical characteristics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob. Agents Chemother. 41:1871-1875.
272. Watanabe, H., U. Kragh-Hansen, S. Tanase, K. Nakajou, M. Mitarai, Y. Iwao, T. Maruyama, and M. Otagiri. 2001. Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants. Biochem. J. 357:269-274.
273. Weinshilboum, R. 2003. Inheritance and drug response. N. Engl. J. Med. 348:529-537.
274. Weinshilboum, R. 1989. Methyltransferase pharmacogenetics. Pharmacol. Ther. 43:77-90.
275. Weinshilboum, R. M., D. M. Otterness, and C. L. Szumlanski. 1999. Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annu. Rev. Pharmacol. Toxicol. 39:19-52.
276. White, T. C. 1997. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 41:1482-1487.
277. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
278. Widersten, M., W. R. Pearson, A. Engstrom, and B. Mannervik. 1991. Heterologous expression of the allelic variant mu-class glutathione transferases mu and psi. Biochem. J. 276:519-524.
279. Wijnholds, J., E. C. deLange, G. L. Scheffer, D. J. van den Berg, C. A. Mol, M. van der Valk, A. H. Schinkel, R. J. Scheper, D. D. Breimer, and P. Borst. 2000. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J. Clin. Investig. 105:279-285.
280. Wildfeuer, A., J. Faergemann, H. Laufen, G. Pfaff, T. Zimmermann, H. P. Seidl, and P. Lach. 1994. Bioavailability of fluconazole in the skin after oral medication. Mycoses 37:127-130.
281. Willems, L., R. van der Geest, and K. de Beule. 2001. Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics. J. Clin. Pharm. Ther. 26:159-169.
282. Williams, M. P., J. Sercombe, M. I. Hamilton, and R. E. Pounder. 1998. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 12:1079-1089.
283. Winkelmann, B. R., and J. Hager. 2000. Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. Pharmacogenomics 1:73-94.
284. Wright, R. M., and R. W. Warpula. 2004. Geriatric pharmacology: safer prescribing for the elderly patient. J. Am. Podiatr Med. Assoc. 94:90-97.
285. Xie, C. X., L. T. Piecoro, and D. P. Wermeling. 1997. Gender-related considerations in clinical pharmacology and drug therapeutics. Crit. Care Nurs. Clin. N. Am. 9:459-468.
286. Yeganeh, M. H., and A. J. McLachlan. 2002. In-vitro distribution of terbinafine in rat and human blood. J. Pharm. Pharmacol. 54:277-281.
287. Yuasa, I., S. Weidinger, K. Umetsu, K. Suenaga, G. Ishimoto, B. C. Eap, J. C. Duche, and P. Baumann. 1993. Orosomucoid system: 17 additional orosomucoid variants and proposal for a new nomenclature. Vox Sang. 64:47-55.
288. Zhang, L., C. M. Brett, and K. M. Giacomini. 1998. Role of organic cation transporters in drug absorption and elimination. Annu. Rev. Pharmacol. Toxicol. 38:431-460.
289. Zollner, G., P. Fickert, R. Zenz, A. Fuchsbichler, C. Stumptner, L. Kenner, P. Ferenci, R. E. Stauber, G. J. Krejs, H. Denk, K. Zatloukal, and M. Trauner. 2001. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology 33:633-646.